CytoDyn’s Two-Year Update on Its PRO 140 Monotherapy Study in HIV Accepted at CROI 2017 Nov 16, 2016 6:30am EST
CytoDyn Announces Webcast of Investment Community Presentation on November 11 Nov 09, 2016 6:30am EST
CytoDyn Files Protocol for Extended Access to PRO 140 for Patients Who Reach the End of PRO 140 Pivotal Phase 3 Trial Oct 24, 2016 6:30am EDT
CytoDyn Announces Favorable Protocol Modifications for Pivotal Phase 3 Combination Trial With PRO 140 After Positive FDA Meeting Oct 06, 2016 6:30am EDT
CytoDyn to Present at Rodman & Renshaw Global Investment Conference on September 12 Sep 07, 2016 5:25pm EDT
Patients Approach Two Years of Complete HIV Viral Load Suppression in Phase 2b PRO 140 Monotherapy Extension Study Aug 23, 2016 6:30am EDT
First Patient Enrolled Under Newly Modified Protocol in CytoDyn’s Phase 3 PRO 140 Combination Study in HIV Jul 26, 2016 6:30am EDT
CytoDyn Submits Orphan Drug Application to FDA for Pretreatment With PRO 140 of Treatment-Naïve HIV Patients Jul 21, 2016 6:30am EDT
